Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The TMEM106B-GRN-TDP43 triad: leveraging human samples and humanized models to unravel FTLD-TDP disease mechanisms

Award Number: R01AG084672
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

The TMEM106B-GRN-TDP43 triad: leveraging human samples and humanized models to unravel FTLD-TDP disease mechanisms - ABSTRACT Frontotemporal lobar degeneration (FTLD) is a group of progressive neurodegenerative disorders that represents 10-20% of all dementias. FTLD profoundly impacts core human qualities including personality, insight and verbal communication and often affects individuals before the age of 65. Aggregates of the TAR DNA-binding protein 43 (TDP-43) in the frontal and temporal lobes are the most common FTLD pathology (FTLD- TDP); however, in-vivo models to study TDP-43 aggregation and/or dysfunction are not currently available, hampering our ability to perform mechanistic studies with translational potential. For example, Grn-deficient mice, which model the loss of progranulin (PGRN), a major cause of FTLD-TDP in humans, develop neuroinflammatory changes but not TDP-43 pathology or overt neuronal loss. This may be partly explained by the fact that mouse microglia cannot fully recapitulate all aspects of human microglial physiology. It is also possible that additional genetic factors, such as the transmembrane protein 106B (TMEM106B) risk haplotype, contribute to disease susceptibility in patients. In support of this theory, it was shown that in GRN carriers the presence of at least one copy of the TMEM106B risk haplotype is a near prerequisite for developing FTLD-TDP. While the specific functional variant(s) that characterize the TMEM106B haplotypes has remained elusive, accumulating evidence suggests the risk haplotype exerts its disease-modifying effect by increasing TMEM106B levels. Considering the findings above, we hypothesize that the genetic risk profile of an individual shapes its cellular responses and phenotypes, thereby promoting particular disease states and modifying the vulnerability of neurons to degeneration. We propose to study this concept in the context of FTLD-TDP using the established disease gene GRN and its genetic modifier TMEM106B in the following specific aims: 1) Generate a humanized FTLD-TDP model. In this aim, the novel MIGRATE protocol developed in the Mancuso lab will be used to transplant patient-derived GRN-deficient microglia in the brain of human TMEM106B overexpressing mice, followed by in-depth neuropathological and functional characterization; 2) Identify molecular players that microglia secrete to induce FTLD-related changes in neurons. Here, we will use our humanized FTLD-TDP mouse model and apply a proximity labeling strategy to define the human-specific secretome associated with GRN deficiency. Candidate disease proteins will be further evaluated as therapeutic targets using antibody treatment in mice and/or biomarkers in human CSF; and 3) Determine the functional variant(s) and regulatory mechanism of the TMEM106B risk haplotype in individual brain cell-types using human samples. Here, we will use our unique cohorts of FTLD brain tissues to perform unbiased single nuclei analyses of transcriptomic and epigenomic changes resulting from haplotype-associated TMEM106B variants. Functional validation of candidate variants will be performed in human iPSCs. Together, the proposed studies will lead to a better understanding and improved ability to diagnose and treat patients with FTLD and other TDP-43 proteinopathies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $527,612 )
2025	2025	VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY	SUZANNE TASSIERSTRAAT 1	GENT				BEL	Aging Research	001	2	7/28/2025	NON-COMPETING CONTINUATION	$527,612
2025	2024	VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY	SUZANNE TASSIERSTRAAT 1	GENT				BEL	Aging Research	000	1	5/6/2025	NEW	$0
														Subtotal = $527,612

Issue Date FY: 2024 ( Subtotal = $538,380 )
2024	2024	VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY	SUZANNE TASSIERSTRAAT 1	GENT				BEL	Aging Research	000	1	9/9/2024	NEW	$538,380
														Subtotal = $538,380

Grand Total All Awards = $1,065,992

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The TMEM106B-GRN-TDP43 triad: leveraging human samples and humanized models to unravel FTLD-TDP disease mechanisms

Award Number: R01AG084672

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer